This transcript is automatically generated
What is the biggest health care events of the year hundreds of companies thousands of investors at the JPMorgan annual conference this week.
It's really in pharmaceuticals is one of them the Biotech company in -- showcase its latest developments in the fight against cancer.
Joining us now on a Fox Business exclusive from San Francisco.
All of our -- are the CEO president of throwing pharmaceuticals Oliver thank you for being here.
-- announcements from you in the areas of -- -- cancer gastric cancer but it's about nano technology.
Using -- technology to target cancer cells explain how that works.
Carol it's a pleasure to be here thank you very much and I look forward to talk about nano technology.
So what we do is very simple in concept we take medicines and package them and small -- -- Why would you do that you do that so that you can actually target tumor tissue tumors.
Have basket it should meaning blood vessels that is more -- so you can make these small balls of just the right size that they fits with a leaky -- -- -- into the tumor.
And don't distribute to the rest of the body so -- would you do that what's the point of doing that and packaging medicines that way it gives -- preferential.
Exposure in the tumor -- you want the drug to do its work with out giving you the toxicity is that we know from so many cancer.
Targeting the bad cells and then spend against -- certainly that is the hope for the future and that's consumer things are going I don't ask you about the environment right now you're at the JPMorgan conference this is -- conference.
For Biopharma I'm curious what the -- now as with BCG just got a big round in December 13 million dollars for you're company.
But I'm curious if companies like -- are having a more difficult time finding.
Funding finding financing and are you gonna go for partnerships do you think the BBC lines are gonna stay open how do you feel right now.
-- lots of great questions what we are seeing in the marketplace -- that last year clearly valuations increase for Biotech the FDA has support to unprecedented number of new drugs.
That's really really exciting and forms a very nice backdrop.
On which to build successful companies so -- and is also blessed by having a very very strong syndicate of investors so we have been able.
To really raise the kind of money that we need to develop our lead molecule in the next -- and as well.
Which for the into the clinic in the middle of this -- so -- been not easy but it's certainly been a manageable proposition that.
A lot of IPOs in 2012 in your in your sector better than 2011 though to be fair but some of the names have actually been.
Strong performer super necessarily while -- -- -- -- mother's.
Do you foresee.
An IPO do you even think that way anymore or is that more about having a private partnership.
One toll has to look at all of these facets and the bond does not exclude the other so partnerships are very important and our business given the long development time -- to get a medicine to market.
On the other hand the IPO environment is very encouraging and I think for quality stories such as facility and story there should be.
The receptivity in the marketplace for and I feel maybe at some point in time.
Do you think though overall that we're gonna seen a more plot bigger pick up an activity this year and Biotech in particular us after that frankly was.
Was hit in in the mid two thousands.
Like many other sectors -- you can -- is still gonna pick up there because of promising therapies like yours.
I think the pick up is already under way we're seeing -- we're seeing as I've mentioned FDA approving more drugs we're seeing investors getting rewarded -- investing.
In Biotech stocks were seeing -- appeal is also doing well in the aftermarket -- enough to launch performance all of these.
Indicators that -- heading in the right direction which is very exciting.
OK all right well I've got some breaking news on -- -- -- -- pharmaceuticals CEO president thank you.
Very much for joining us -- fox business -- telling -- fall in that conference spirit it is.